Dendritic Cells: a Critical Player in Cancer Therapy?

Overview

Journal J Immunother

Specialty Allergy & Immunology

Date 2008 Oct 4

PMID 18833008

Citations 29

Authors

Anna Karolina Palucka

Hideki Ueno

Joseph Fay

Jacques Banchereau

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or active, that is, vaccination. Early clinical trials testing vaccination with ex vivo generated dendritic cells (DCs) pulsed with tumor antigens provide a proof-of-principle that therapeutic immunity can be elicited. Yet, the clinical benefit measured by regression of established tumors in patients with stage IV cancer has been observed in a fraction of patients only. The next generation of DC vaccines is expected to generate large numbers of high avidity effector CD8 T cells and to overcome regulatory T cells and suppressive environment established by tumors, a major obstacle in metastatic disease. Therapeutic vaccination protocols will combine improved DC vaccines with chemotherapy to exploit immunogenic chemotherapy regimens. We foresee adjuvant vaccination in patients with resected tumors but at high risk of relapse to be based on in vivo targeting of DCs with fusion proteins containing anti-DCs antibodies, antigens from tumor stem/propagating cells, and DC activators.

Citing Articles

Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models.

Tokhanbigli S, Alavifard H, Aghdaei H, Zali M, Baghaei K Bioimpacts. 2023; 13(4):333-346.

PMID: 37645031 PMC: 10460770. DOI: 10.34172/bi.2022.24209.

GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma.

Huang R, Pan J, Zhang Y, Qin Q, Chao N, Huang T J Healthc Eng. 2022; 2022:2518847.

PMID: 35070229 PMC: 8767371. DOI: 10.1155/2022/2518847.

Profiling of the immune landscape in murine glioblastoma following blood brain/tumor barrier disruption with MR image-guided focused ultrasound.

Sheybani N, Witter A, Garrison W, Miller G, Price R, Bullock T J Neurooncol. 2021; 156(1):109-122.

PMID: 34734364 PMC: 8714701. DOI: 10.1007/s11060-021-03887-4.

Melatonin administration provokes the activity of dendritic reticular cells in the seminal vesicle of Soay ram during the non-breeding season.

Abd-Elhafeez H, Hassan A, Hussein M Sci Rep. 2021; 11(1):872.

PMID: 33441634 PMC: 7806754. DOI: 10.1038/s41598-020-79529-y.

Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.

Amon L, Hatscher L, Heger L, Dudziak D, Lehmann C Pharmaceutics. 2020; 12(7).

PMID: 32674488 PMC: 7408110. DOI: 10.3390/pharmaceutics12070663.

References

Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

Verdijk P, Aarntzen E, Punt C, de Vries I, Figdor C . Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther. 2008; 8(7):865-74. DOI: 10.1517/14712598.8.7.865. View

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

Sallusto F, Lanzavecchia A . Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med. 1999; 189(4):611-4. PMC: 2192930. DOI: 10.1084/jem.189.4.611. View

Dorrie J, Schaft N, Muller I, Wellner V, Schunder T, Hanig J . Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother. 2007; 57(4):467-77. PMC: 11041385. DOI: 10.1007/s00262-007-0385-1. View

Munn D, Mellor A . Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007; 117(5):1147-54. PMC: 1857253. DOI: 10.1172/JCI31178. View

Dong C . TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008; 8(5):337-48. DOI: 10.1038/nri2295. View

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

10.

Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T . Dendritic cell subsets in health and disease. Immunol Rev. 2007; 219:118-42. DOI: 10.1111/j.1600-065X.2007.00551.x. View

11.

Sinha P, Clements V, Fulton A, Ostrand-Rosenberg S . Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9):4507-13. DOI: 10.1158/0008-5472.CAN-06-4174. View

12.

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

13.

Chaput N, Darrasse-Jeze G, Bergot A, Cordier C, Ngo-Abdalla S, Klatzmann D . Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol. 2007; 179(8):4969-78. DOI: 10.4049/jimmunol.179.8.4969. View

14.

Hava D, Brigl M, van den Elzen P, Zajonc D, Wilson I, Brenner M . CD1 assembly and the formation of CD1-antigen complexes. Curr Opin Immunol. 2005; 17(1):88-94. DOI: 10.1016/j.coi.2004.12.003. View

15.

Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari A . Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res. 2005; 65(18):8479-86. DOI: 10.1158/0008-5472.CAN-05-1319. View

16.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A . A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007; 30(1):1-15. DOI: 10.1097/01.cji.0000211341.88835.ae. View

17.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

18.

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

19.

Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View

20.

Thornton A, Shevach E . CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 188(2):287-96. PMC: 2212461. DOI: 10.1084/jem.188.2.287. View